Pulse Biosciences Inc. Announces Successful Initial Procedures in PRECISE-BTN Study for Benign Thyroid Nodule Treatment

Reuters

Sep 02

<a href="https://laohu8.com/S/PLSE">Pulse Biosciences</a> Inc. Announces Successful Initial Procedures in PRECISE-BTN Study for Benign Thyroid Nodule Treatment

Pulse Biosciences Inc. has announced the successful commencement of procedures in the PRECISE Benign Thyroid Nodule (BTN) Study, utilizing its proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology. This multicenter clinical study, approved by the IRB, is designed to treat benign thyroid nodules using the nsPFA™ Percutaneous Electrode System. The study aims to enroll up to 50 patients across four sites, with follow-up evaluations at 1, 3, 6, and 12 months to assess safety, nodule volume reduction, symptom reduction, and quality of life improvements. Initial procedures have been successfully conducted, and early positive results are being observed, with further updates anticipated as patient follow-ups continue.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250902946787) on September 02, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2564305809"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564305809\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564305809?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-02 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564305809","market":"us","top_or_hot":-1,"title":"Pulse Biosciences Inc. Announces Successful Initial Procedures in PRECISE-BTN Study for Benign Thyroid Nodule Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PLSE\">Pulse Biosciences</a> Inc. Announces Successful Initial Procedures in PRECISE-BTN Study for Benign Thyroid Nodule Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Pulse Biosciences Inc. has announced the successful commencement of procedures in the PRECISE Benign Thyroid Nodule (BTN) Study, utilizing its proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology. This multicenter clinical study, approved by the IRB, is designed to treat benign thyroid nodules using the nsPFA™ Percutaneous Electrode System. The study aims to enroll up to 50 patients across four sites, with follow-up evaluations at 1, 3, 6, and 12 months to assess safety, nodule volume reduction, symptom reduction, and quality of life improvements. Initial procedures have been successfully conducted, and early positive results are being observed, with further updates anticipated as patient follow-ups continue.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250902946787) on September 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pulse Biosciences Inc. Announces Successful Initial Procedures in PRECISE-BTN Study for Benign Thyroid Nodule Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPulse Biosciences Inc. Announces Successful Initial Procedures in PRECISE-BTN Study for Benign Thyroid Nodule Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-02 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PLSE\">Pulse Biosciences</a> Inc. Announces Successful Initial Procedures in PRECISE-BTN Study for Benign Thyroid Nodule Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Pulse Biosciences Inc. has announced the successful commencement of procedures in the PRECISE Benign Thyroid Nodule (BTN) Study, utilizing its proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology. This multicenter clinical study, approved by the IRB, is designed to treat benign thyroid nodules using the nsPFA™ Percutaneous Electrode System. The study aims to enroll up to 50 patients across four sites, with follow-up evaluations at 1, 3, 6, and 12 months to assess safety, nodule volume reduction, symptom reduction, and quality of life improvements. Initial procedures have been successfully conducted, and early positive results are being observed, with further updates anticipated as patient follow-ups continue.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250902946787) on September 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nNDL33WlHs:1","article_id":"2564305809","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564305809","pubTimestamp":1756810886,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Pulse Biosciences Inc. has announced the successful commencement of procedures in the PRECISE Benign Thyroid Nodule  Study, utilizing its proprietary Nanosecond Pulsed Field Ablation  technology. This multicenter clinical study, approved by the IRB, is designed to treat benign thyroid nodules using the nsPFA Percutaneous Electrode System. The study aims to enroll up to 50 patients across four sites, with follow-up evaluations at 1, 3, 6, and 12 months to assess safety, nodule volume reduction, symptom reduction, and quality of life improvements. Initial procedures have been successfully conducted, and early positive results are being observed, with further updates anticipated as patient follow-ups continue.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","PLSE":"Pulse Biosciences, Inc."},"translate_title":"Pulse Biosciences Inc.宣布在PRECISE-BTN良性甲状腺结节治疗研究中成功进行初始手术","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLSE":0.9},"content_text":"Pulse Biosciences Inc. Announces Successful Initial Procedures in PRECISE-BTN Study for Benign Thyroid Nodule Treatment\n    \n\n        Pulse Biosciences Inc. has announced the successful commencement of procedures in the PRECISE Benign Thyroid Nodule (BTN) Study, utilizing its proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology. This multicenter clinical study, approved by the IRB, is designed to treat benign thyroid nodules using the nsPFA™ Percutaneous Electrode System. The study aims to enroll up to 50 patients across four sites, with follow-up evaluations at 1, 3, 6, and 12 months to assess safety, nodule volume reduction, symptom reduction, and quality of life improvements. Initial procedures have been successfully conducted, and early positive results are being observed, with further updates anticipated as patient follow-ups continue.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250902946787) on September 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}